Non-alcoholic fatty liver disease (NAFLD) was barely described in medical literature before 1980. A 1980 Mayo Clinic paper by Ludwig et al. identified a group of patients with liver pathology that looked like alcoholic liver disease but who didn’t drink. The authors named the condition and noted, tentatively, that obesity seemed to be a factor.

By 2023, NAFLD affects an estimated 25% of the global adult population. In the United States, the number is closer to 30-40%. It’s now the most common liver disease in the world, and the rise tracks almost precisely with the trajectory of high-fructose corn syrup use in the food supply.

Why the Liver

The liver’s role in fructose metabolism is what makes it specifically vulnerable to high-sugar diets in a way other organs aren’t.

Glucose is distributed throughout the body for energy use. Roughly 80% of ingested glucose goes to peripheral tissues, muscle, brain, kidneys, and the liver handles the rest.

Fructose is different. Virtually all dietary fructose is extracted from the portal blood by the liver on first pass. The liver is the primary, and in most circumstances, nearly exclusive, site of fructose metabolism. When you eat a moderate amount of fruit, the liver handles the fructose comfortably as fuel. When you drink a 20-ounce sweetened beverage delivering 30-40 grams of fructose in minutes, the liver receives more fructose than it can use for immediate energy.

The excess gets converted to fat through de novo lipogenesis. That fat can accumulate within liver cells (hepatocytes), impairing liver function and triggering inflammation.

The Progression of NAFLD

NAFLD exists on a spectrum:

Simple steatosis (fatty liver): Fat accumulates in hepatocytes without significant inflammation or damage. Largely asymptomatic. Often discovered incidentally on imaging for another condition. Considered reversible with dietary changes.

Non-alcoholic steatohepatitis (NASH): Fat accumulation plus inflammation and hepatocyte injury. NASH is the clinically significant form. Some patients with NASH experience no symptoms; others develop fatigue and right upper quadrant discomfort. NASH can progress to cirrhosis.

Cirrhosis: Scar tissue replaces healthy liver tissue. Irreversible. Impairs liver function, including blood filtration, protein synthesis, and bile production. Can lead to liver failure and hepatocellular carcinoma.

Hepatocellular carcinoma: Liver cancer arising from cirrhotic tissue. NAFLD-related cirrhosis is now one of the leading indications for liver transplant in the United States.

Approximately 20-25% of people with simple steatosis develop NASH. Approximately 20% of those with NASH develop cirrhosis over 20 years.

Fructose as Driver

The mechanistic link from fructose to NAFLD is well-established in animal models and strongly supported by human data.

In human feeding studies, fructose overfeeding (providing excess calories entirely from fructose) produces liver fat accumulation within one to two weeks. Glucose overfeeding at equivalent caloric excess produces less liver fat accumulation. The specificity of fructose’s lipogenic effect appears to be due to fructose bypassing phosphofructokinase. The regulatory enzyme that would otherwise limit the rate at which glucose enters the fat synthesis pathway.

A 2009 study by Stanhope et al. in the Journal of Clinical Investigation compared 10 weeks of glucose vs. fructose supplementation at 25% of caloric intake in overweight adults. The fructose group showed significantly higher rates of de novo lipogenesis, increased liver fat, and worsening markers of cardiovascular risk (elevated LDL, triglycerides, apolipoprotein B). The glucose group showed none of these changes.

The Alcoholic Fatty Liver Parallel

The comparison between NAFLD and alcoholic liver disease is instructive and not coincidental. Ethanol is metabolized by the liver through a pathway that also produces acetyl-CoA, the substrate for fat synthesis. High alcohol consumption overloads the same hepatic fat synthesis pathways that excess fructose overloads, which is why the pathological appearance of the two conditions is nearly identical.

Robert Lustig has argued that fructose and ethanol are metabolically analogous: both are metabolized primarily in the liver, both are converted to fat when intake exceeds immediate energy needs, both elevate triglycerides and uric acid, and both carry dose-dependent toxicity. The public health argument he draws from this (that fructose should be regulated similarly to alcohol) remains controversial, but the biochemical parallels are accepted by most hepatologists.

What’s Changed in the Food Supply

HFCS was introduced commercially in the US around 1975. By 1984, Coca-Cola and Pepsi had switched their formulas from sucrose to HFCS-55. By 1990, HFCS had become the dominant sweetener in processed food. The NAFLD epidemic begins in the 1980s and accelerates through the 1990s and 2000s.

This correlation doesn’t establish causation — other factors changed over the same period. But it is one of the more striking temporal alignments in nutrition epidemiology.

Diagnosis and Prevalence

NAFLD is diagnosed by liver imaging (ultrasound, CT, MRI) or biopsy. Blood tests can suggest liver inflammation (elevated ALT and AST), but normal liver enzymes don’t rule out NAFLD. Many people with significant liver fat have normal blood tests.

The FIB-4 index (a calculation using age, ALT, AST, and platelet count) is used to estimate fibrosis stage non-invasively. Liver elastography (FibroScan) measures liver stiffness as a proxy for fibrosis.

Approximately 25% of global adults have NAFLD. Among obese adults, the prevalence is 75-90%. Among people with type 2 diabetes, 70-80%. Among normal-weight adults in Western countries, approximately 7-10%, illustrating that obesity is a major risk factor but not a prerequisite.

Reversal

Simple steatosis is reversible. Weight loss of 7-10% of body weight, achieved through diet and exercise, consistently reduces liver fat on imaging. Carbohydrate restriction (particularly fructose restriction) produces faster liver fat reduction than equivalent caloric restriction with less carbohydrate reduction.

NASH reversal is possible with weight loss of 10%+ but harder to achieve and sustain. No pharmacological treatments for NAFLD/NASH were FDA-approved as of 2024, though several were in late-stage trials.

NAFLD-related cirrhosis is not reversible, though progression can be slowed.

References